Novo Nordisk A/S (NVO)
| Market Cap | 271.64B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 15.54 |
| Forward PE | 16.40 |
| Dividend | $1.23 (2.00%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 12,952,954 |
| Open | 62.30 |
| Previous Close | 61.85 |
| Day's Range | 60.72 - 62.32 |
| 52-Week Range | 45.05 - 135.20 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 98.00 (+59.61%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $98.0, which is an increase of 59.61% from the latest price.
News
Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel
CNBC's “Fast Money” team discusses new obesity drug data and the market leaders, including Novo Nordisk and Eli Lilly, with Dr. Kavita Patel, NBC News and MSNBC medical contributor.
Novo Nordisk: Don't Be Deterred By Outlook Downgrades
Novo Nordisk A/S's repeated downgrades in outlook might spook investors, but here I argue that there's still much to like about it. Stemming from a restructuring plan, if the latest outlook reduction ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Inside the Race to Launch GLP-1 Weight-Loss Pills
Plus, solar cars, Meta's new glasses and AI financial agents, in this edition of The Future of Everything newsletter.
Wall Street Breakfast Podcast: FedEx Delivers Earnings Surprise
FedEx (FDX) surges after beating FQ1 earnings expectations, reporting revenue growth, and advancing its FedEx Freight spin-off, targeted for June 2026. Cracker Barrel (CBRL) faces renewed activist pre...
Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
Novo Nordisk's recent stock decline looks like a market overreaction to a lot of noise, presenting a strong long-term buying opportunity at a discounted price. The new CEO's restructuring could improv...
GOOGL, NVO, Small Caps & Other Value Plays in All-Time High Market
Jeff McClean says A.I. valuations have ballooned to the point where the value in many have been lost.
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reu...
Novo Nordisk shares surge after Wegovy pill trial shows ‘significant' weight reduction
CNBC's Angelica Peebles reports on Novo Nordisk shares surging after the company announced that its Wegovy pill trial showed ‘significant' weight reduction.
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
Novo Nordisk shares climb after positive results for anti-obesity pill
Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss' with tablet version of Wegovy
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Novo Nordisk A/S NVO looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is startin...
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closer
Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.
It Is Time To Buy Novo Nordisk Hand Over Fist
Novo Nordisk A/S remains a Strong Buy, driven by restructuring, pipeline advancements, and robust product developments like the Wegovy pill. NVO's restructuring will cut 9,000 jobs, saving $1.27B annu...
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit - NVO
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk shares rise 5% on upbeat analyst reaction to diabetes conference
Novo Nordisk shares rose 5% on Thursday following positive analyst reactions to an investor meeting that company executives held at the European Association for the Study of Diabetes conference.
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.
In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semagluti...
Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds
Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.
Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment ...
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Novo Nordisk A/S - Special Call
Novo Nordisk A/S - Special Call Company Participants Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Martin Parkhoi - SEB, Research Division Michael Novo...
Novo Nordisk says Wegovy pill shows comparable weight-loss to injectable version
Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The New England Journal of Medicine on Wednesday, which is comparable to previo...
Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the inves...